Phase II study of chemoradiotherapy with S-1 plus cisplatin for clinical stage IA esophageal cancer (definitive chemoradiotherapy) - Phase II study of chemoradiotherapy with S-1 plus cisplatin for clinical stage IA esophageal cancer (definitive chemoradiotherapy)

Osaka International Cancer Institute0 个研究点目标入组 38 人开始时间: 2014年7月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Simultaneous or metachronous double cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer 2) Patients requiring the administration of phenytoin or warfarin potassium 3) Uncontrollable diabetes millutus 4) History of myocardial infarction within 6 months, or unstable angina pectoris or cardiac failure 5) Uncontrollable arrhythmia 6) Patients requiring systemic steroids medication 7) Liver cirrhosis 8) Active bacterial or fungous infection 9) With a history of grade 2-4 allergic reaction by CTCAE version 4.0 10) With grade 2-4 nerve disturbance by CTCAE version 4.0 11) With blood transfusion within 2 weeks and/or active bleeding 12) Interstitial pneumonia, fibroid lung or severe emphysema 13) With a history of allergic reaction to tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) 14) Psychosis 15) Pregnant or lactating women, women of childbearing potential or men who like to have children in future 16) Any patients judged by the investigator to be unfit to participate in the study

发起方